01Partner development
Direct GMP partnerships
Direct relationships with qualified pharmaceutical manufacturers, supported by technical assessment, vendor qualification and quality agreements.
UK pharmaceutical company
Building a more resilient pharmaceutical supply network.
NovaPharm Healthcare brings together regulatory intelligence, diversified sourcing, quality-led distribution and digital infrastructure to improve access to oncology, specialty and licensed medicines.
Pre-operational for regulated wholesale supply · B2B only · Subject to applicable MHRA authorisation
UK pharmaceutical companyCompliance-first modelB2B healthcare partnershipsQuality-led sourcingTechnology-enabled infrastructure
Three-pillar sourcing
Three routes. One governed supply strategy.
The proposed model is designed to diversify regulatory, geographic and supplier dependencies without lowering the evidence required for each product.
Each route remains subject to its own qualification, regulatory and commercial evidence. Photography is representative.
02Regulatory preparation
Product-specific PLPI pathways
Assessment of appropriate EEA-authorised medicines for UK parallel-import pathways, subject to product-specific applications and MHRA approval.
03Network development
European buying network
A proposed network of qualified manufacturers, authorised distributors and licensed wholesalers across selected European markets.
Qualified route evidenceGoverned portfolio decisionResilienceQualityAvailabilityCost discipline
Oncology & specialty focus
Explore the oncology continuity modelSpecialised categories require specialised operating discipline.
NovaPharm's planned portfolio prioritises categories where sourcing, demand, storage, documentation and continuity need closer attention.
Oral oncology formulation planningLiquid formulation evidenceSpecialty and hard-to-source categoriesProduct-specific readinessControlled-temperature governance where applicable
Regulatory foundation
No regulated supply before the required permissions.
The roadmap connects authorisation, quality systems and product-specific responsibilities before commercial release.
- 01Authorisation
WDA(H) application readiness
- 02Product pathway
Product-specific PLPI assessment
- 03Quality system
QMS and SOP governance
- 04Distribution control
GDP and vendor oversight
- 05Safety system
Pharmacovigilance and recall readiness
- 06Evidence trail
Batch and document integrity
- 07Release gate
Commercial release only after applicable authorisation
Batch integrity
Evidence should travel with every governed product and transaction.
Product identity, batch, expiry, source documents, quality status, custody and customer records should remain connected through each controlled step.
Product and source identityBatch and expiry evidenceQuality and release statusCustody and transaction record
01 / Operations
Logistics & distribution
A capital-efficient third-party model, governed as an outsourced pharmaceutical activity.
NovaPharm plans to integrate with Polar Speed/Marken for pharmaceutical storage, transport and delivery services. The relationship, scope, locations, performance commitments and system interfaces remain subject to final contract, authorisation and onboarding.
Explore logistics operationsClinical Research & CRO Support
Connect clinical-development decisions to the evidence and UK pathway that follow.
NovaPharm's evidence-led model combines programme framing, responsibility mapping, UK pathway coordination and qualified specialist orchestration. It is not presented as a global full-service CRO.
- 01Programme question
- 02Responsibility map
- 03Controlled evidence
- 04UK pathway
- 05Market continuity
Technology maturity
Tell people what is live, what is being built and what remains planned.
NovaPharm's digital architecture separates working foundations from development and roadmap claims.
Live
Public company platform
Responsive corporate website, structured entity content, account application and controlled public information.
In development
Secure role-based portals
Customer, employee, board and administrator applications backed by the Node runtime and server-side scope enforcement.
Planned
AI-assisted demand forecasting
A proposed forecasting capability that will require governed source data, model validation, monitoring and human oversight.
Partner ecosystem
Designed for qualified pharmaceutical collaboration.
Each pathway has a distinct evidence boundary, operating context and commercial purpose.
Introduction does not equal approval. Every route moves through fit, due diligence, agreement and controlled implementation.
01
Manufacturing and development
GMP manufacturers, CMO and CDMO organisations, product owners and dossier holders.
02
Authorised sourcing
European and UK licensed wholesalers assessed through defined qualification controls.
03
Market access
Pharmacy groups, hospital procurement and qualified account pathways, subject to applicable authorisation.
04
Enabling infrastructure
Logistics, quality, regulatory, data and technology specialists.
Photography and generated editorial imagery are representative. They do not identify a NovaPharm-owned facility, current partner, authorised product or active regulated supply operation unless explicitly stated.
Featured insights
Original analysis for regulated pharmaceutical operators.
Educational perspectives on regulation, quality, supply and technology, written in British English and reviewed against NovaPharm's claims guardrails.
Regulatory
Building a Compliance-First Pharmaceutical Distribution Model in the UK
A practical framework for designing a UK pharmaceutical distribution business in which authorisation, quality governance and commercial operations develop in the right order.
Technology
From Batch to Buyer: Designing More Traceable Pharmaceutical Supply Chains
A practical architecture for connecting product, batch, temperature, custody, order, customer and quality records without overstating blockchain or automation maturity.
Quality
GDP, QMS and the Practical Foundations of Reliable Pharmaceutical Distribution
How Good Distribution Practice and a proportionate Quality Management System turn pharmaceutical policies into controlled, reviewable daily operations.
Start a qualified conversation